Sermorelin vs HGH: Comparing Growth Hormone Research Approaches (UK 2026)

For researchers studying the growth hormone axis, a fundamental question is whether to use recombinant human growth hormone (rhGH) directly or to stimulate endogenous GH release using a GH secretagogue such as sermorelin. The distinction matters enormously for study design — each approach produces a different GH profile, different downstream IGF-1 dynamics, different feedback loop engagement, and different safety profiles. This guide compares sermorelin and recombinant HGH as research tools for understanding the GH axis.

Growth Hormone Physiology: Pulsatile Release

Endogenous GH secretion is characterised by pulsatile release — discrete bursts of GH secreted throughout the day and night, with the largest pulses occurring shortly after sleep onset during slow-wave sleep. Between pulses, basal GH levels are very low — near or below assay detection limits. This pulsatile pattern is not merely a pharmacological detail; it is physiologically essential. Somatotroph cells in the pituitary are exposed to alternating waves of GHRH (stimulatory) and somatostatin (inhibitory) from the hypothalamus, and the pulsatile GH output is the product of this oscillating signal integration.

The pulsatile GH pattern has specific downstream consequences: pulsatile GH exposure of hepatocytes produces greater IGF-1 stimulation than continuous GH exposure at the same total dose — reflecting pulse-sensitive receptor dynamics. Many of GH’s metabolic effects (lipolysis, glucose homeostasis, IGF-1 production) are calibrated to this pulsatile biology. Departing from pulsatile GH delivery — as rhGH administration does — produces pharmacological effects that differ from those of the physiological pulsatile GH signal.

Recombinant HGH: Supraphysiological and Non-Pulsatile

Recombinant human GH (rhGH; somatropin) is a 191-amino-acid protein identical in sequence to pituitary-derived GH, produced by recombinant DNA technology. When administered subcutaneously (as is standard), rhGH produces a sustained pharmacokinetic profile — peak levels within 2–4 hours of injection, declining over 12–24 hours. This is a non-pulsatile, pharmacokinetic profile entirely unlike the endogenous pulsatile pattern.

Administered at clinical doses, rhGH produces GH concentrations substantially above physiological peak pulse levels. This supraphysiological elevation produces robust IGF-1 stimulation and anabolic effects, but also engages insulin resistance mechanisms and other GH excess effects that would not occur with physiological GH pulses.

Critically, exogenous rhGH suppresses endogenous GH secretion through negative feedback: elevated GH and IGF-1 stimulate somatostatin release and inhibit GHRH, suppressing pituitary GH output during and after rhGH administration. This HPG axis suppression means that rhGH studies are investigating exogenous hormone replacement rather than stimulation of the endogenous GH axis — a fundamentally different experimental condition.

Sermorelin: Physiological Stimulation of Endogenous GH

Sermorelin (GRF 1-29 NH₂) is a synthetic 29-amino-acid peptide corresponding to the first 29 amino acids of native GHRH — the biologically active fragment of the 44-amino-acid endogenous hormone. It binds GHRH receptors (GHRHR) on pituitary somatotrophs with high affinity, stimulating GH synthesis and release through the same Gs-protein/cAMP/PKA pathway as endogenous GHRH.

The key distinction from rhGH: sermorelin stimulates the pituitary’s own GH secretion rather than supplying exogenous GH. This means:

Preserved pulsatility: The pituitary response to sermorelin is a natural GH pulse — amplitude and duration constrained by the somatotroph’s endogenous secretory capacity. The resulting GH peak is physiological in character (though enhanced), not the sustained pharmacokinetic profile of rhGH.

Intact negative feedback: Because GH and IGF-1 elevation is produced by the pituitary, the normal feedback mechanisms remain engaged — somatostatin is released in response to GH elevation, limiting the duration of each GH pulse. This self-regulation prevents supraphysiological accumulation and maintains the basic biology of the feedback loop.

Pituitary dependence: Sermorelin can only produce GH if the pituitary is functional. In GH deficiency due to pituitary damage or absence, sermorelin is ineffective — making it diagnostic as well as therapeutic (a sermorelin stimulation test that fails to produce GH elevation indicates pituitary insufficiency).

IGF-1 Dynamics: Pulsatile vs Sustained

The liver converts GH pulses into sustained IGF-1 secretion — IGF-1 has a longer half-life than GH and acts as the primary mediator of many of GH’s anabolic effects. Sermorelin-driven GH pulses produce hepatic IGF-1 responses that remain within or slightly above the physiological range for age. rhGH produces IGF-1 elevations that are typically supraphysiological at therapeutic doses — IGF-1 levels above age-matched reference ranges are common in rhGH-treated patients.

For research designs studying the physiological GH/IGF-1 axis, sermorelin produces more physiological IGF-1 dynamics. For designs requiring specific supraphysiological IGF-1 levels as an experimental variable, rhGH provides more precise control over the IGF-1 dose.

Research Application Comparison

Studying endogenous GH axis regulation: Sermorelin is the appropriate tool — it probes the pituitary’s responsiveness and the integrity of the GHRH/GH/somatostatin feedback loop. GH stimulation tests using sermorelin diagnose pituitary GH reserve.

Studying supraphysiological GH/IGF-1 effects: rhGH is the appropriate tool — it delivers controlled doses of GH independent of pituitary function, allowing precise manipulation of GH and IGF-1 levels without HPG axis variability.

GH deficiency models: Both are relevant but answer different questions. rhGH replacement directly replaces the missing hormone. Sermorelin tests whether the pituitary has residual secretory capacity — relevant for partial GH deficiency models.

Ageing and GH decline research: Sermorelin is particularly relevant for studying age-related GH decline, where the problem is reduced GHRH drive to a still-functional pituitary rather than pituitary failure per se. Sermorelin can restore GH pulsatility in aged animals where hypothalamic GHRH tone is reduced — a more physiologically accurate intervention than rhGH replacement in this context.

Summary

The choice between sermorelin and rhGH as GH axis research tools reflects fundamentally different experimental objectives. Sermorelin interrogates the endogenous GH axis — pituitary responsiveness, GHRH signalling, physiological GH pulsatility, and age-related hypothalamic decline — while maintaining intact feedback regulation and producing physiological GH/IGF-1 profiles. rhGH bypasses the endogenous axis entirely, providing exogenous hormone replacement with precise, non-pulsatile, supraphysiological GH delivery. Both are valid research tools; the appropriate choice depends entirely on whether the research question concerns the endogenous GH regulatory system or the downstream effects of GH/IGF-1 at specific concentrations.